The relationship between Eli Lilly and Donald Trump is multifaceted. While the corporation itself engages in standard political lobbying and advocacy to represent its business interests, media reports have noted that financial portfolios managed on behalf of Donald Trump have included substantial investments in Eli Lilly stock. These investments have often coincided with periods where federal policy and government initiatives—such as those related to healthcare and drug pricing—directly impacted the pharmaceutical industry. While the company maintains its own corporate political action committee to support various candidates across the political spectrum, the specific financial ties between the former president's personal investments and the company’s stock performance are a matter of public financial disclosure.